SpectraScience, Inc. to Host Shareholder Update Call on February 28, 2011 at 1:00pm Pacific Time

SAN DIEGO, CA--(Marketwire - February 23, 2011) - SpectraScience, Inc. (OTCBB: SCIE), a San Diego based medical device company, today announced that it will hold a conference call to provide a general corporate update and answer questions on Monday, February 28, 2010 at 1:00pm pacific time.

The management team will host the conference call to discuss various operational aspects of the business in addition to corporate goals and initiatives for the remainder of fiscal year 2011. To attend the call, please use the dial in information below. When prompted, ask for the “SpectraScience Investor Update Conference Call” and/or be prepared to provide the conference ID.

Conference Call

Date: Monday, February 28, 2011
Time: 1:00 pm Pacific Time
Conference Line Dial-In (U.S.): 1-877-941-1428
International Dial-In: 1-480-629-9665
Conference ID: 4417172

Please dial in at least 10 minutes before the call to ensure timely participation. A playback of the call will be available from 8:00 pm Eastern Time on February 28, 2011 until 11:59 pm ET on March 14, 2011. To listen, call 1-877-870-5176 within the United States or 1-858-384-5517 when calling internationally. Please use the replay pin number 4417172.

In the event that you would prefer to listen to the conference call on your computer, please click on the following link at the scheduled conference call time: http://viavid.net/dce.aspx?sid=0000821B

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company’s LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.